About ReproGo
ReproGo is an award-winning regenerative medicine company dedicated to advancing therapies for incurable conditions resulting from the deterioration or loss of blood vessels.
​
Our groundbreaking technology facilitates the restoration of blood vessel function in any organ or tissue.
​
We are committed to providing patients with hope and healing through our innovative approach to regenerative medicine.
We are award-winning vascular scientists and stem cell experts,
committed to fighting vascular disease
MISSION
ReproGo is committed to transforming the treatment paradigm for millions of patients grappling with severe and life-threatening conditions resulting from limited blood flow to tissues. This is especially crucial for diabetic individuals at heightened risk of limb amputation and related health challenges. At the forefront of our efforts is a pioneering program centred around iPSC-derived vasculogenic cells, for creating fresh blood vessels in oxygen-deprived tissues.
SUSTAINABLE MANUFACTURING
​​ReproGo's technology markedly minimises or eliminates the requirement for animal testing, prioritising shorter, xeno-free, low-dose and eco-friendly biomanufacturing for cell reprogramming and cell differentiation. Our streamlined approach guides therapeutic candidates from early R&D to clinical (cGMP). Our facilities adhere to iPSC industry standards, ensuring compliance for product release while promoting sustainability and minimising waste.
HISTORY
ReproGo, a Deep Tech startup originating from Queen's University Belfast, is at the forefront of advanced stem cell-based technology. Founded by Prof. Andriana Margariti and led by co-founder and CEO Dr. Sophia Kelaini, ReproGo boasts a rich research history spanning over two decades. It identified vascular dysfunction and reduced blood flow as major contributors to various diseases and mortality, including diabetic complications, stroke, heart disease, and chronic wounds.
TECHNOLOGY
ReproGo targets vascular diseases, with its patent-pending techniques for the efficient creation of vascular cells and advanced organoids. Its iPSC-derived vascular cells offer exceptional purity, longevity and boast cost-effectiveness and sustainability advantages over traditional cell therapies. Gaining access to Nobel Prize winning technologies through established partnerships, its objective is to progress a donor-independent, allogeneic cell replacement therapy.